title: Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to methicillin-sensitive bacteriemia.
abstract: Bacteriemia due to coagulase-negative staphylococci (CNS) resistant to methicillin and sensitive only to glycopeptides in 220 cancer patients was prospectively analyzed for risk factors and outcome. A group of 33 cases of bacteriemia with CNS-sensitive only to glycopeptides was compared with a group of 187 cases with CNS sensitive to methicillin. All cases appeared in two affiliated major cancer institutes in Bratislava with the same antibiotic policy. Univariate analysis showed differences in recorded risk factors: acute leukemia (48 vs. 33%, P < 0.05), neutropenia (57 vs. 32%, P < 0.045), previous prophylaxis with quinolones (30 vs. 11%, P < 0.01) and penicillin-V (15 vs. 3%, P < 0.02) and previous colonisation with CNS (27 vs. 3%, P < 0.01) were more frequently associated with bacteriemia resistant to methicillin and sensitive only to glycopeptides. Attributable mortality was also higher in this subgroup in comparison to bacteriemias with CNS sensitive to methicillin (12 vs. 3%, P < 0.05) however, overall mortality was similar. Bacteriemias due to CNS caused by sensitivity only to glycopeptides occurred more frequently in neutropenic patients (1), with acute leukemia (2), receiving quinolone and penicillin prophylaxis (3), and previously colonized (4), patients and had worse prognosis in comparison to those with methicillin-sensitive staphylococcal bacteriemias.
authors.affiliation: Department of Oncology, Elizabeth Cancer Institute, School of Public Health, University of Trnava, Slovak Republic.
authors.forename: Z
authors.initials: Z
authors.lastname: Horváthová
authors.forename: S
authors.initials: S
authors.lastname: Spánik
authors.forename: J
authors.initials: J
authors.lastname: Sufliarsky
authors.forename: J
authors.initials: J
authors.lastname: Mardiak
authors.forename: P
authors.initials: P
authors.lastname: Pichna
authors.forename: E
authors.initials: E
authors.lastname: Pichnova
authors.forename: S
authors.initials: S
authors.lastname: Krajcík
authors.forename: M
authors.initials: M
authors.lastname: Mráz
authors.forename: B
authors.initials: B
authors.lastname: Chmelík
authors.forename: J
authors.initials: J
authors.lastname: Dacok
authors.forename: J
authors.initials: J
authors.lastname: Beresova
authors.forename: I
authors.initials: I
authors.lastname: Krúpová
authors.forename: A
authors.initials: A
authors.lastname: Hrachová
authors.forename: J
authors.initials: J
authors.lastname: Trupl
authors.forename: A
authors.initials: A
authors.lastname: Kunová
authors.forename: V
authors.initials: V
authors.lastname: Krcméry
mesh_terms: D019072:Antibiotic Prophylaxis / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016470:Bacteremia / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D016106:Methicillin Resistance; D009503:Neutropenia / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000453:epidemiology* / Q000209:etiology; D013212:Staphylococcus epidermidis
chemical_list: D000970:Antineoplastic Agents